GlassScriptPhysician profile
Frances Ann Mateo
NPI 1548976038
$2,142.00
in general payments reported to CMS, 2019-2025
18 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $192 · 2024: $440 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $471.03 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $409.47 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $245.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $205.03 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $165.47 | 2025 | |
| Amgen INC. | $130.46 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $124.83 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.62 | 2025 | |
| Glaxosmithkline, LLC. | $55.49 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $48.94 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $33.92 | 2025 | Contrave |
| Stryker Corporation | $29.79 | 2025 | Clottriever Bold Catheter |
| Shield Therapeutics INC | $29.62 | 2025 | |
| Corium, LLC | $27.66 | 2023 | Azstarys |
| Organon LLC | $22.09 | 2025 | Nexplanon |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.05 | 2025 | Voquezna |
| Abbott Laboratories | $18.35 | 2023 | Diamondback Coronary |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.84 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Ann Mateo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.